Potabicarbonate/potassium citratessium bicarbonate/potassium citrate - Advicenne

Drug Profile

Potabicarbonate/potassium citratessium bicarbonate/potassium citrate - Advicenne

Alternative Names: ADV 7103; Potassium citrate monohydrated/potassium hydrogen carbonate - Advicenne; Potassium citrate/potassium bicarbonate - Advicenne; Potassium hydrogen carbonate/potassium citrate monohydrated - Advicenne

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator Advicenne
  • Class Alkalinising agents; Electrolytes; Small molecules; Urologics
  • Mechanism of Action Electrolyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kidney disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase III Kidney disorders

Most Recent Events

  • 05 Jul 2017 Potassium bicarbonate/potassium citrate - Advicenne receives Orphan Drug status for Kidney disorders in European Union
  • 20 May 2016 Advicenne Pharma completes a phase-II/III trial in Kidney disorders (In infants, In children, In adolescents, In adults) in Slovakia (EudraCT2013-002988-25)
  • 05 Oct 2015 Phase-II/III clinical trials in Kidney disorders in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top